PolTREG is partnering with Antion Biosciences to develop next-generation allogeneic TREG therapies, the company announced in a press release.
As reported, the planned result of the cooperation will be the use of the Swiss company's technology and CAR-TREG therapy developed by PolTREG to develop and commercialize a new generation of allogeneic TREGS “off-the-shelf (ready for immediate use) therapies with increased immunomodulatory activity for the treatment of autoimmune and neurodegenerative diseases.
“Under the agreement, PolTREG has obtained exclusivity for the development and commercialization of products based on TREG lymphocytes and Antion Biosciences technology in the treatment of autoimmune and neurodegenerative diseases. PolTREG will cover most of the costs associated with
further development of the Antion Biosciences platform in TREG lymphocytes, which will be reflected in the division of revenues from the potential commercialization of the technology,” it added.
It was reported that Antion Biosciences technology is currently at the preclinical testing stage. Assuming positive development of the developed drug and marketing authorization, the agreement gives PolTREG unlimited rights to the applied IP and know-how. (PAP Biznes)
mbi/ gor/
